raloxifene bismethyl ether hydrochloride

Raloxifene Bismethyl Ether hydrochloride is a Raloxifene metabolite and an estrogen receptor inactive compound on which both hydroxyl groups are absent.

Raloxifene hydrochloride (LY156758 hydrochloride) is a second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.

Compound 7, or Raloxifene 6-Monomethyl Ether, is a derivative of Raloxifene that effectively inhibits estrogen receptor α. It also displays the inhibitory effects on MCF-7 cells, with an IC50 of 250 nM and a pIC50 of 6.6.

Raloxifene Bismethyl Ether is a Raloxifene metabolite and an estrogen receptor inactive compound on which both hydroxyl groups are absent.

Raloxifene 4-Monomethyl Ether (Compound 37) is a derivative of Raloxifene which acts as an inhibitor of estrogen receptor α. It effectively suppresses the activity of MCF-7 cells, exhibiting an IC50 value of 1 μM and a pIC50 value of 6.

Thalidomide 4'-ether-alkylC2-amine hydrochloride (halidomide-linker 6) is a synthesized E3 ligase ligand-linker conjugate.

Raloxifene dimethyl ester hydrochloride is an analog of Raloxifene.

Raloxifene (LY-139481) is a selective oestrogen receptor modulator. It has effects on bone and breast cancer and cardiovascular disease risk.